The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130
Abstract
Studies in IL-6-deficient (IL-6−/−) mice highlight that IL-6 contributes to arthritis progression. However, the molecular mechanism controlling its activity in vivo remains unclear. Using an experimental arthritis model in IL-6−/− mice, we have established a critical role for the soluble IL-6R in joint inflammation. Although intra-articular administration of IL-6 itself was insufficient to reconstitute arthritis within these mice, a soluble IL-6R-IL-6 fusion protein (HYPER-IL-6) restored disease activity. Histopathological assessment of joint sections demonstrated that HYPER-IL-6 increased arthritis severity and controlled intrasynovial mononuclear leukocyte recruitment through the CC-chemokine CCL2. Activation of synovial fibroblasts by soluble IL-6R and IL-6 emphasized that these cells may represent the source of CCL2 in vivo. Specific blockade of soluble IL-6R signaling in wild-type mice using soluble gp130 ameliorated disease. Consequently, soluble IL-6R-mediated signaling represents a promising therapeutic target for the treatment of rheumatoid arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemokines and leukocyte traffic
Baggiolini, M. (1998) · Nature · doi:10.1038/33340 · Cited by 2,709
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Self-citationRole of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment
Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., Faggioni, R., Luini, W., van Hinsbergh, V., Sozzani, S., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80334-9 · Cited by 1,112
Houssiau, F. A., Devogelaer, J., Damme, J. V., Deuxchaisnes, C. N. D., & Snick, J. V. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310614 · Cited by 847
Hurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N., & Jones, S. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00151-0 · Cited by 811
Self-citationSoluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
Jostock, T., Müllberg, J., Özbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M. F., & Rose‐John, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01867.x · Cited by 641
Self-citationThe soluble interleukin 6 receptor: mechanisms of production and implications in disease
JONES, S. A., HORIUCHI, S., TOPLEY, N., YAMAMOTO, N., & FULLER, G. M. (2001) · The FASEB Journal · doi:10.1096/fj.99-1003rev · Cited by 623
Self-citationInterleukin 6 is required for the development of collagen-induced arthritis
Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De Benedetti, F., Poli, V., & Ciliberto, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.461 · Cited by 604
Wipke, B. T., & Allen, P. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1601 · Cited by 585
Cited by
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
Self-citationRecent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Self-citationInterleukin-6, a Major Cytokine in the Central Nervous System
Erta, M., Quintana, A., & Hidalgo, J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4679 · Cited by 1,087
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040
“Rheumatoid Arthritis Antigen induced arthritis, collagen induced arthritis [8, 34, 64]”
BackgroundSelf-citationInterleukin-6 Family Cytokines
Rose-John, S. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 799
Self-citationDirecting Transition from Innate to Acquired Immunity: Defining a Role for IL-6
Jones, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.3463 · Cited by 771
Self-citationInterleukin-6 in Aging and Chronic Disease: A Magnificent Pathway
Maggio, M., Guralnik, J. M., Longo, D. L., & Ferrucci, L. (2006) · The Journals of Gerontology: Series A · doi:10.1093/gerona/61.6.575 · Cited by 692
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose-John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683
Self-citationRose-John, S., Scheller, J., Elson, G., & Jones, S. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1105674 · Cited by 647
Self-citationIL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
Neurath, M. F., & Finotto, S. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.02.003 · Cited by 576
Targeting IL-6 trans-signalling: past, present and future prospects
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524
Self-citationInterleukin-6: Biology, signaling and strategies of blockade
Schaper, F., & Rose-John, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.004 · Cited by 509
Self-citationThe role of interleukin-6 signaling in nervous tissue
Rothaug, M., Becker-Pauly, C., & Rose-John, S. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.018 · Cited by 491
Il-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance
Mudter, J., & Neurath, M. F. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20148 · Cited by 436
The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition
Garbers, C., Aparicio-Siegmund, S., & Rose-John, S. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.008 · Cited by 429
Self-citationThe role of IL-6 in host defence against infections: immunobiology and clinical implications
Rose-John, S., Winthrop, K., & Calabrese, L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.83 · Cited by 424
Self-citationVersatile functions for IL-6 in metabolism and cancer
Mauer, J., Denson, J. L., & Brüning, J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.008 · Cited by 407
Plasticity and cross-talk of Interleukin 6-type cytokines
Garbers, C., Hermanns, H. M., Schaper, F., Müller-Newen, G., Grötzinger, J., Rose-John, S., & Scheller, J. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.04.001 · Cited by 400
Self-citationRheumatic diseases: the effects of inflammation on bone
Walsh, N. C., Crotti, T. N., Goldring, S. R., & Gravallese, E. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00338.x · Cited by 380
The IL-6/sIL-6R complex as a novel target for therapeutic approaches
Rose-John, S., Waetzig, G. H., Scheller, J., Grötzinger, J., & Seegert, D. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.5.613 · Cited by 360
Self-citationThe role of Interleukin 6 in the pathophysiology of rheumatoid arthritis
Srirangan, S., & Choy, E. H. (2010) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10378372 · Cited by 357
The varying faces of IL-6: From cardiac protection to cardiac failure
Fontes, J. A., Rose, N. R., & Čiháková, D. (2015) · Cytokine · doi:10.1016/j.cyto.2014.12.024 · Cited by 337
The shedding protease ADAM17: Physiology and pathophysiology
Zunke, F., & Rose-John, S. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.07.001 · Cited by 336
Self-citationIL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation
McLoughlin, R. M., Jenkins, B. J., Grail, D., Williams, A. S., Fielding, C. A., Parker, C. R., Ernst, M., Topley, N., & Jones, S. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501794102 · Cited by 333
Self-citationChalaris, A., Rabe, B., Paliga, K., Lange, H., Laskay, T., Fielding, C. A., Jones, S. A., Rose-John, S., & Scheller, J. (2007) · Blood · doi:10.1182/blood-2007-01-067918 · Cited by 329
Self-citationIL-6 biology: implications for clinical targeting in rheumatic disease
Calabrese, L. H., & Rose-John, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.127 · Cited by 328
Self-citationRivollier, A., Mazzorana, M., Tebib, J., Piperno, M., Aitsiselmi, T., Rabourdin-Combe, C., Jurdic, P., & Servet-Delprat, C. (2004) · Blood · doi:10.1182/blood-2004-01-0041 · Cited by 323
Nociceptive neurons detect cytokines in arthritis
Schaible, H.-G. (2014) · Arthritis Research & Therapy · doi:10.1186/s13075-014-0470-8 · Cited by 319
Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities
Scheller, J., Garbers, C., & Rose-John, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2013.11.002 · Cited by 308
Self-citationInterleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
Harmer, D., Falank, C., & Reagan, M. R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00788 · Cited by 307
Interleukin‐6 Trans‐Signalling in Chronic Inflammation and Cancer
Scheller, J., Ohnesorge, N., & Rose‐John, S. (2006) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01750.x · Cited by 297
Self-citationInterleukin-6 and its receptor: from bench to bedside
Scheller, J., & Rose-John, S. (2006) · Medical Microbiology and Immunology · doi:10.1007/s00430-006-0019-9 · Cited by 292
Self-citationThe soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
Chalaris, A., Garbers, C., Rabe, B., Rose-John, S., & Scheller, J. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.10.007 · Cited by 289
Self-citationTherapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
Dayer, J.-M., & Choy, E. (2010) · Rheumatology · doi:10.1093/rheumatology/kep329 · Cited by 267
Baran, P., Hansen, S., Waetzig, G. H., Akbarzadeh, M., Lamertz, L., Huber, H. J., Ahmadian, M. R., Moll, J. M., & Scheller, J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001163 · Cited by 235
Nowell, M. A., Williams, A. S., Carty, S. A., Scheller, J., Hayes, A. J., Jones, G. W., Richards, P. J., Slinn, S., Ernst, M., Jenkins, B. J., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.613 · Cited by 215
Self-citationQin, H., Wilson, C. A., Lee, S. J., Zhao, X., & Benveniste, E. N. (2005) · Blood · doi:10.1182/blood-2005-02-0759 · Cited by 205
Jones, G. W., McLoughlin, R. M., Hammond, V. J., Parker, C. R., Williams, J. D., Malhotra, R., Scheller, J., Williams, A. S., Rose-John, S., Topley, N., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901528 · Cited by 189
Self-citationThe soluble interleukin 6 receptor: advanced therapeutic options in inflammation
Rose‐John, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.782 · Cited by 169
Self-citationTargeting classical IL-6 signalling or IL-6 trans-signalling in depression?
Maes, M., Anderson, G., Kubera, M., & Berk, M. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.888417 · Cited by 140
ten Berge, J. C., Fazil, Z., van den Born, L. I., Wolfs, R. C. W., Schreurs, M. W. J., Dik, W. A., & Rothova, A. (2019) · Acta Ophthalmologica · doi:10.1111/aos.13899 · Cited by 118
Sleep enhances IL‐6 trans‐signaling in humans
Dimitrov, S., Lange, T., Benedict, C., Nowell, M. A., Jones, S. A., Scheller, J., Rose‐John, S., Born, J., Dimitrov, S., Lange, T., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-5754fje · Cited by 115
Self-citationOld and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development
Sardar, S., & Andersson, Å. (2016) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1125917 · Cited by 50
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?
Avci, A. B., Feist, E., & Burmester, G. R. (2024) · BioDrugs · doi:10.1007/s40259-023-00634-1 · Cited by 50
The Regenerative Activity of Interleukin-6
Galun, E., & Rose-John, S. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-308-4_4 · Cited by 34
Self-citation
Metadata
- Authors
- Nowell, M. A., Richards, P. J., Horiuchi, S., Yamamoto, N., Rose-John, S., Topley, N., Williams, A. S., & Jones, S. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-09
- Volume
- 171
- Issue
- 6
- Pages
- 3202-3209
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1849537180
- Cited by
- 268
- References
- 51
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.